Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer

BACKGROUND: Programmed cell death 1 (PD-1) is an inhibitory immune checkpoint expressed on activatedT cells. Upon the formation of T cell receptor (TCR)-pMHC complexes, concomitant PD-1 ligation to its ligands programmed death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2) downregulates TCR s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuang, Zhang, Min, Wu, Weiwei, Yuan, Zhijun, Tsun, Andy, Wu, Min, Chen, Bingliang, Li, Jia, Miao, Xiaoniu, Miao, Xiaoliang, Liu, Xiaolin, Yu, Dechao, Liu, Junjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990132/
https://www.ncbi.nlm.nih.gov/pubmed/30406214
http://dx.doi.org/10.1093/abt/tby005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990132/
https://www.ncbi.nlm.nih.gov/pubmed/30406214
http://dx.doi.org/10.1093/abt/tby005

Ejemplares similares